지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Recent advances in incretin biology have led to the development of a new class of oral anti-diabetic drugs. To date, there are twoknown incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), of which theformer is a more important therapeutic target for type 2 diabetes. GLP-1 is secreted by intestinal L-cells in response to oral nutrientintake, and it stimulates insulin secretion and suppresses glucagon secretion in a glucose-dependent manner. However, both GLP-1and GIP are rapidly degraded by dipeptidyl peptidase-4 (DPP-4), a multifunctional type II transmembrane glycoprotein. Thus,several DPP-4 inhibitors with different pharmacologic features are now available and can be used either as monotherapy or incombination with other anti-diabetic agents for the treatment of type 2 diabetes. In both therapeutic regimens, DPP-4 inhibitorshave been shown to reduce hemoglobin A1c levels by approximately 0.5-0.8%. In clinical trials, DPP-4 inhibitors were generallywell-tolerated, posed a low risk of hypoglycemia, and did not increase body weight. Despite some reports of a possible increasedrisk of pancreatitis with GLP-1 receptor agonists and DPP-4 inhibitors, no causal associations have been found. Recent randomizedcontrolled clinical trials have shown that DPP-4 inhibitors did not increase or decrease the rates of major adverse cardiovascularevents in patients with type 2 diabetes at high risk of cardiovascular disease, even though this class of anti-diabetic agents hadvarious salutary effects in many studies involving animals or healthy and diabetic humans. Additional studies will be required toresolve these disparate conclusions.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
Baetta R / 2011 / Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences / Drugs 71 : 1441 ~ 1467
Baggio LL / 2007 / Biology of incretins: GLP-1 and GIP / Gastroenterology 132 : 2131 ~ 2157
Boonacker E / 2003 / The multifunctional or moonlighting protein CD26/DPPIV / Eur J Cell Biol 82 : 53 ~ 73
Butler AE / 2013 / Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for gluca
Cordero OJ / 2009 / On the origin of serum CD26 and its altered concentration in cancer patients / Cancer Immunol Immunother 58 : 1723 ~ 1747
Baggio LL / 2007 / Biology of incretins: GLP-1 and GIP / Gastroenterology 132 : 2131 ~ 2157
Boonacker E / 2003 / The multifunctional or moonlighting protein CD26/DPPIV / Eur J Cell Biol 82 : 53 ~ 73
Butler AE / 2013 / Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for gluca
Cordero OJ / 2009 / On the origin of serum CD26 and its altered concentration in cancer patients / Cancer Immunol Immunother 58 : 1723 ~ 1747
이 논문의 저자 정보
최근 본 자료
댓글(0)
0